Methods for treating graft-versus-host disease, methods for reducing symptoms of graft-versus-host disease, and methods of reducing the severity of graft-versus-host disease in a patient are disclosed.

To provide a novel remedy for graft-versus-host disease (GVHD).

A second stent (15) is positioned in the passage (14) of the tubular graft to expand the graft against the interior surface of the migrating stent graft (30).

A combination of interleukin-10 and cyclosporin is used to suppress graft-versus-host disease, autoimmune diseases and tissue/graft rejection.

Acute graft versus host disease (GvHD) is one of the most significant clinical problems in allogeneic blood and marrow transplantation.

Methods for treating autoimmune disease, graft rejection, and graft- versus- host disease, as well as methods for reducing activated T cells are provided.

The composition and method of the invention may also be used for the induction of graft tolerance, for the prevention of graft-v.-host disease.

The invention relates to the novel use of gene markers in a method of predicting the risk of or diagnosing a subject to develop graft versus host reaction (GvHR) or graft versus host disease (GvHD).

The invention relates to a specific antibody directed against, for use for treating graft versus host disease.

The present invention provides a non-human model system for graft-versus-host disease.

Depletion of CD8+ T cells from the donor lymphocyte infusion reduces the risk of sustained engraftment and graft-versus-host disease.

In order to prevent graft vs. host disease complications, the allogeneic cells can be irradiated prior to infusion.

Methods are disclosed for treating or preventing graft versus host disease in a subject.

Graft versus host disease (GvHD) is a condition that might occur after an allogeneic transplant.

The group is particularly interested in developing strategies to reduce the incidence and severity of graft versus host disease while maintaining an immunotherapeutic graft-versus-tumor effect.